Lysosomal Therapeutics
US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.
Founded
2011US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.
Founded in Cambridge, Massachusetts, Lysosomal Therapeutics Inc (LTI) is dedicated to pioneering small-molecule research and development aimed at treating neurodegenerative diseases. The company's core mission is to discover and develop innovative therapies that address the underlying causes of severe neurological conditions, thereby improving patient outcomes. LTI focuses on leveraging lysosomal biology to create novel treatment options, positioning itself at the forefront of neurodegeneration research.
Notable figures affiliated with LTI include leading scientists and industry experts in the field of neurobiology. The company has attracted significant investment from prominent venture capital firms specializing in biotech innovations. Key achievements include advancing several promising drug candidates through preclinical stages, demonstrating potential efficacy in targeting neurodegenerative pathways. LTI's work has had a substantial impact on the scientific community, contributing valuable insights into the mechanisms of neurological diseases and fostering hope for effective treatments.
Companies similar to Lysosomal Therapeutics include Endlyz Therapeutics, Denali Therapeutics, Arkuda Therapeutics and Libra Therapeutics.
Lysosomal Therapeutics was founded in 2011.
Lysosomal Therapeutics' headquarters is located in Cambridge, MA, US.
Lysosomal Therapeutics' most recent funding round was for $20M (USD) in February 2015.
As of Feb 3, 2015, Lysosomal Therapeutics has disclosed funding of $24.8M (USD). Undisclosed round amounts are excluded.
Lysosomal Therapeutics has 5 employees as of Feb 5, 2024.
Libra Therapeutics
